H.C. Wainwright Maintains Rigel Pharmaceuticals(RIGL.US) With Buy Rating, Maintains Target Price $15

H.C. Wainwright analyst Joseph Pantginis maintains $Rigel Pharmaceuticals(RIGL.US)$ with a buy rating, and maintains the target price at $15.According to TipRanks data, the analyst has a success rate

moomoo NewsJun 17 06:33 ET · Ratings

Rigel Announces Five Presentations at the EHA2024 Hybrid Congress

- Oral presentation highlighting final five-year efficacy data from the registrational Phase 2 trial of REZLIDHIA(olutasidenib) in heavily pretreated patients with R/R mIDH1 AML, including those

PR NewswireJun 14 03:05 ET

Rigel Highlights New Data in Three Poster Presentations at the 2024 ASCO Annual Meeting

Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced the presentation of three posters at the 2024 American Society of Clinical Oncology (ASCO) ...

PR NewswireJun 3 08:13 ET

Rigel to Present at the Jefferies Global Healthcare Conference

Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that Raul Rodriguez, the company's president and CEO, will present a company overview at...

PR NewswireMay 30 08:05 ET

Rigel Pharmaceuticals' Strategic Resolutions at 2024 Annual Meeting

TipRanksMay 30 03:13 ET

Rigel Announces Presentations at the Upcoming 2024 ASCO Annual Meeting and EHA2024 Hybrid Congress

Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced upcoming presentations from their commercial and clinical-stage hematology and oncology...

PR NewswireMay 23 17:00 ET